ISSUE 1392
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved the antiprogestin mifepristone (Korlym – Corcept Therapeutics) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes/glucose intolerance and have not responded to, or are not candidates for, surgery. Formerly known as RU 486, mifepristone is also available in a lower strength as Mifeprex for use in terminating an early intrauterine pregnancy.
MECHANISM OF ACTION — Mifepristone is a synthetic steroid with a high affinity for progesterone receptors that acts as an antiprogestin. At higher doses, it also binds strongly to glucocorticoid receptors and, to a lesser extent, androgen receptors.
TREATMENT OF CUSHING'S SYNDROME — The definitive treatment of Cushing's syndrome is surgical removal of the pituitary or adrenal tumor causing the excessive production of cortisol. The
... more1. NA Tritos and BM Biller. Advances in medical therapies for Cushing's syndrome. Discov Med 2012; 13:171.
4. Whole acquisition cost (WAC). Source: PricePointRx™. Reprinted with permission by FDB. All rights reserved. ©2012. http://www.firstdatabank.com/support/drug-pricing-policy.aspx. Accessed June 1, 2012. Actual retail prices may be higher.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1392c
Electronic, downloadable article - $45
